elobixibat
{{Short description|Chemical compound}}
{{Drugbox
| drug_name =
| image = Elobixibat skeletal.svg
| alt =
| caption =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_category=
| routes_of_administration = By mouth
| ATCvet =
| ATC_prefix = A06
| ATC_suffix = AX09
| ATC_supplemental = {{ATCvet|A06|AX09}}
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 439087-18-0
| PubChem = 9939892
| DrugBank = DB12486
| ChemSpiderID = 8115513
| ChEMBL = 3039515
| UNII = 865UEK4EJC
| KEGG = D10796
| IUPAC_name = N-
| C = 36 | H = 45 | N = 3 | O = 7 | S = 2
| smiles = O=C(O)CNC(=O)[C@@H](c1ccccc1)NC(=O)COc4cc3c(N(c2ccccc2)CC(CS3(=O)=O)(CCCC)CCCC)cc4SC
| StdInChI = InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
| StdInChIKey = XFLQIRAKKLNXRQ-UUWRZZSWSA-N
}}
Elobixibat is an inhibitor of the ileal bile acid transporter (IBAT),{{cite web|title=INN for A3309 is ELOBIXIBAT |url=http://www.albireopharma.com/News.aspx?PageID=494131 |publisher=AlbireoPharma |access-date=5 December 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120118024525/http://www.albireopharma.com/News.aspx?PageID=494131 |archive-date=18 January 2012 }} undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C).
Mechanism of action
Elobixibat is an inhibitor of IBAT, which is an alternative name for the apical sodium bile acid transporter (ASBT) encoded by the SLC10A2 gene. ASBT/IBAT is a bile acid:sodium symporter responsible for the reuptake of bile acids in the ileum, the initial step in their enterohepatic circulation. By inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool. Following several phase II studies, it is now undergoing phase III trials.{{cite journal |vauthors=Acosta A, Camilleri M |title=Elobixibat and its potential role in chronic idiopathic constipation |journal=Therap Adv Gastroenterol |volume=7 |issue=4 |pages=167–75 |year=2014 |pmid=25057297 |pmc=4107709 |doi=10.1177/1756283X14528269 }}
Drug development
The drug was developed by Albireo AB, who licensed it to Ferring Pharmaceuticals for further development and marketing.{{cite web|last1=Grogan|first1=Kevin|title=Ferring acquires rights to Albireo's bowel drug|url=http://www.pharmatimes.com/news/ferring_acquires_rights_to_albireo_bowel_drug_977026|website=PharmaTimes|date=4 July 2012|access-date=23 March 2017}} Albireo has partnered with Ajinomoto Pharmaceuticals, giving the Japan-based company the rights to further develop the drug and market it throughout Asia.{{cite web|title=Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat |url=http://www.albireopharma.com/News.aspx?PageID=741677 |archive-url=https://archive.today/20130116164940/http://www.albireopharma.com/News.aspx?PageID=741677 |url-status=dead |archive-date=16 January 2013 |publisher=Albireo |access-date=5 December 2012 }} In India, Dr. Reddy's Laboratories launched Elobixibat with brand name Bixibat in October 2024.{{Cite web |date=2024-12-09 |title=India’s CDSCO gives nod to sell 19 new drugs in 2024 |url=https://www.fortuneindia.com/macro/outlook-2025-indias-cdsco-gives-nod-to-sell-19-new-drugs-in-2024/119658 |archive-url=https://web.archive.org/web/20250123064932/https://www.fortuneindia.com/macro/outlook-2025-indias-cdsco-gives-nod-to-sell-19-new-drugs-in-2024/119658#google_vignette |archive-date=2025-01-23 |access-date=2025-01-23 |website=www.fortuneindia.com |language=en}}
References
{{reflist}}